MX2007012619A - Tratamiento de neumonia severa adquirida en comunidad por administracion de inhibidor de ruta de factor de tejido. - Google Patents

Tratamiento de neumonia severa adquirida en comunidad por administracion de inhibidor de ruta de factor de tejido.

Info

Publication number
MX2007012619A
MX2007012619A MX2007012619A MX2007012619A MX2007012619A MX 2007012619 A MX2007012619 A MX 2007012619A MX 2007012619 A MX2007012619 A MX 2007012619A MX 2007012619 A MX2007012619 A MX 2007012619A MX 2007012619 A MX2007012619 A MX 2007012619A
Authority
MX
Mexico
Prior art keywords
tfpi
administration
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
MX2007012619A
Other languages
English (en)
Inventor
Abla Creasey
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of MX2007012619A publication Critical patent/MX2007012619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Metodos para tratar profilacticamente o terapeuticamente neumonia severa que comprenden la administracion de inhibidor de ruta de factor de tejio TFPI) o un analogo de TFPI a pacientes que padecen de o estan en riesgo de desarrollar esta condicion. Los metodos comprenden el uso de infusion intravenosa continua de TFPI o un analogo de TFPI, de manera preferente a bajas dosis para evitar efectos secundarios adversos.
MX2007012619A 2005-04-15 2006-04-14 Tratamiento de neumonia severa adquirida en comunidad por administracion de inhibidor de ruta de factor de tejido. MX2007012619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67146605P 2005-04-15 2005-04-15
PCT/US2006/013890 WO2006113360A2 (en) 2005-04-15 2006-04-14 Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor(tfpi)

Publications (1)

Publication Number Publication Date
MX2007012619A true MX2007012619A (es) 2008-01-11

Family

ID=36951247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007012619A MX2007012619A (es) 2005-04-15 2006-04-14 Tratamiento de neumonia severa adquirida en comunidad por administracion de inhibidor de ruta de factor de tejido.

Country Status (13)

Country Link
EP (1) EP1871408A2 (es)
JP (1) JP2008536859A (es)
KR (1) KR20080033151A (es)
CN (1) CN101180074A (es)
AU (1) AU2006236698A1 (es)
BR (1) BRPI0610549A2 (es)
CA (1) CA2605057A1 (es)
IL (1) IL186548A0 (es)
MX (1) MX2007012619A (es)
RU (1) RU2007142192A (es)
TN (1) TNSN07386A1 (es)
WO (1) WO2006113360A2 (es)
ZA (1) ZA200708700B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501111A2 (en) * 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor

Also Published As

Publication number Publication date
CN101180074A (zh) 2008-05-14
ZA200708700B (en) 2008-12-31
EP1871408A2 (en) 2008-01-02
CA2605057A1 (en) 2006-10-26
JP2008536859A (ja) 2008-09-11
WO2006113360A3 (en) 2007-04-12
KR20080033151A (ko) 2008-04-16
IL186548A0 (en) 2008-01-20
BRPI0610549A2 (pt) 2010-07-06
TNSN07386A1 (en) 2009-03-17
WO2006113360A2 (en) 2006-10-26
AU2006236698A1 (en) 2006-10-26
RU2007142192A (ru) 2009-05-20

Similar Documents

Publication Publication Date Title
TNSN07413A1 (en) Use of tfpi to treat severe bacterial infections
MXPA04003548A (es) Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
HK1120409A1 (en) Treatment of diseases by subcutaneous administration of a vegf antagonist
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MX346186B (es) Inhibidores de proteina cinasas.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
TW200742580A (en) Methods for treating nephrolithiasis
SG150552A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2007104933A8 (en) Chemical compounds
IS8373A (is) Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
TW200610524A (en) Medicine for prevention or treatment of diabetes
TW200608965A (en) Medicine for prevention or treatment of diabetes
TW200621794A (en) Pulmonary administration of an antithrombotic compound
NO20075898L (no) Behandling av samfunnsvervet lungebetennelse ved administrering av vevsfaktor pathway inhibitor (TFPI)
EA201070844A1 (ru) ((e)-n-{3-[1-(8-фтор-11h-10-окса-1-аза-дибензо[a,d]циклогептен-5-илиден)пропил]фенил}метансульфонамид) в качестве модулятора рецепторов глюкокортикоидов для лечения ревматизма
UA33293U (ru) Способ лечения хронического эндометрита

Legal Events

Date Code Title Description
FA Abandonment or withdrawal